P934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY FROM GRIFFIN. (23rd June 2022) - Rodriguez, C.; Kaufman, J. L.; Laubach, J.; Sborov, D. W.; Reeves, B.; Chari, A.; Silbermann, R.; Costa, L. J.; Anderson, L. D.; Nathwani, N.; Shah, N.; Bumma, N.; et al.